Your browser doesn't support javascript.
loading
Emerging roles of left ventricular assist device therapy as bridge to transplant in an Asian city with scarce heart transplant donor.
Wong, Ka-Lam; Ho, Ka Lai Cally; Lee, Oswald Joseph; Lun, Kin Shing; Bhatia, Inderjeet; Tam, Wai Ying Eva; Fan, Yue Yan Katherine; Au, Wing Kuk Timmy.
Afiliação
  • Wong KL; Cardiac Medical Unit, Grantham Hospital, Hong Kong, China.
  • Ho KLC; Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China.
  • Lee OJ; Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China.
  • Lun KS; Department of Paediatric Cardiology, Queen Mary Hospital, Hong Kong, China.
  • Bhatia I; Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China.
  • Tam WYE; Cardiac Medical Unit, Grantham Hospital, Hong Kong, China.
  • Fan YYK; Cardiac Medical Unit, Grantham Hospital, Hong Kong, China.
  • Au WKT; Department of Cardiothoracic Surgery, Queen Mary Hospital, Hong Kong, China.
J Thorac Dis ; 13(10): 5717-5730, 2021 Oct.
Article em En | MEDLINE | ID: mdl-34795921
ABSTRACT

BACKGROUND:

Left ventricular assist device (LVAD) has been increasingly used in patients with advanced heart failure. This study aimed to assess the impact of implementation of LVAD therapy on heart transplantation (HTx) service in Hong Kong (HK).

METHODS:

LVAD program was started in 2010 in HK and patients who had been put on HTx waiting list since the start of HTx program in HK from 1992 to 2020 were included for analysis. Survival on HTx waiting list between pre-LVAD era 1992-2009 and post-LVAD era 2010-2020 were analyzed by Kaplan-Meier method and compared by log-rank test. Multivariate analysis by time-dependent Cox-proportional hazard model was used to identify independent predictors of HTx waiting list mortality.

RESULTS:

A total of 478 heart transplant listing episodes involving 457 patients were included for analysis. There were 232 heart transplantations (HTxs), including one re-transplantation, during the study period. There were 110 patients who received LVAD as bridge to transplantation (BTT) and 30 of them had undergone subsequent HTx. The 1-, 2- and 3-year survival on waiting list were 82.3%, 61.7% and 43.0% respectively in the pre-LVAD era (n=178), while the 1-, 2- and 3-year survival were significantly improved at 85.7%, 81.8% and 78% respectively in the post-LVAD era (n=300), (P=0.003). Time-dependent multivariate analysis revealed that LVAD support was independently associated with significant reduction of waiting list mortality [odds ratio (OR) 0.21; 95% confidence interval (CI) 0.10-0.44, P<0.001]. There was no significant difference when comparing survival after LVAD as BTT and survival after HTx up to 8 years (76.1% vs. 72% at 8 years respectively, P=0.732).

CONCLUSIONS:

Waiting list survival improved in the post-LVAD era driven by the implementation of LVAD service. Long-term survival for LVAD recipients as BTT were comparable to heart transplant recipients in HK.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Thorac Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Thorac Dis Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China